| |
cGMP (pmol/mg protein)
|
|---|
| |
Intact
|
Denuded
|
l-NAME 50 μM
|
MB 10 μM
|
Ca2+free medium
|
|---|
|
Control
|
0.53 ± 0.08
|
–
|
–
|
–
|
–
|
|
SNP 10 μM
|
3.45 ± 0.56*
|
–
|
–
|
–
|
–
|
|
ACh 10 μM
|
3.21 ± 0.42*
|
0.60 ± 0.18
|
0.70 ± 0.09
|
0.52 ± 0.12
|
0.45 ± 0.11
|
|
PV 100 μg/ml
|
3.18 ± 0.74*
|
0.57 ± 0.13
|
0.54 ± 0.09
|
0.66 ± 0.07
|
0.64 ± 0.04
|
- After pretreatment with 10 μM IBMX for 5 min, aortic segments were replaced in Ca2+-free Krebs’ (2.5 mM EGTA) buffer or treatment with inhibitors of l-NAME and methylene blue (MB) for 10 min and then sodium nitroprusside (SNP), acetylcholine (ACh) and PV were added for another 2 min. The aortic rings were immersed in liquid nitrogen to stop the reaction. cGMP formation were measured. Data are expressed as the mean ± standard error of the mean (S.E.M) of more than 5 individual experiments. –, not determined. * p < 0.05 indicates a significant difference from the control.
